Making advances where it matters: Improving outcomes in mood and anxiety disorders

CNS Spectrums

Volumn 9, Issue 6 SUPPL. 4, 2004, Pages 14-22

  Golden, Robert N ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; IMIPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGITATION; ANXIETY; ANXIETY DISORDER; CANCER; CLINICAL RESEARCH; COMORBIDITY; CONFERENCE PAPER; CONSTIPATION; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HEADACHE; HEART INFARCTION; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NAUSEA; NERVOUSNESS; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STROKE; XEROSTOMIA;

EID: 3042741900     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900025463     Document Type: Conference Paper

References (70)

1. World Health Organization. World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva: WHO, 2001. Available at: http://www.who. int/whr2001/2001/main/en/chapter2/002el.htm. Accessed March 23, 2004.
2. Von Korff M, Goldberg D. Improving outcomes in depression. BMJ. 2001;323:948-949.
3. Goldberg D, Privet M, Ustun B, Simon G, Linden M. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Br J Gen Pract. 1998;48(437):1840-1844.
4. World Health Organization. Global Burden of Disease: 2000. Geneva: WHO, 2001. Available at: http://www.who.int/whr2001/2001/main/en/chapter2/002.htm. Accessed March 24, 2004.
5. Kessler RC, Berglund P, Demler O. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCSR). JAMA. 2003;289(23):3095-3105.
6. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed. rev. Washington, DC: American Psychiatric Association; 2000.
7. Goodwin FK, Jamison KR. Suicide. In: Manic-Depressive Illness. New York, NY: Oxford University Press; 1990:227-244.
8. Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AE Prevalence of anxiety disorders and their comorbidity with mood and addictive Disorders. Br J Psychiatry Suppl. 1998;43:24-28.
9. Weissman MM, Klerman GL, Markowitz JS, Ouellette R. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med. 1989;321(18):1209-1214.
10. Dunham NC, Sager MA. Functional status, symptoms of depression, and the outcomes of hospitalization in community-dwelling elderly patients. Arch Fam Med. 1994;3(8):676-680.
11. Perez-Stable EJ, Miranda J, Munoz RF, Ying YW. Depression in medical outpatients. Underrecognition and misdiagnosis. Arch Intern Med. 1990;May(5):1083-1088.
12. Rovner BW, German PS, Brant LJ, Clark R, Burton L, Folstein M. Depression and Mortality in Nursing Homes. JAMA. 1991;265(8):993-996.
13. Katon W, von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30(1):67-76.
14. Evans DL, Staab J, Ward H. Depression in the medically ill: management considerations. Depress Anxiety. 1997;4:199-208.
15. Cassem EH. Depressive disorders in the medically ill. An overview. Psychosomatics. 1995;36(2):S2-S10.
16. Katon W, Sullivan. Depression and chronic medical illness. J Clin Psychiatry. 1990;51(S3-11):12-4.
17. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 1996;49(4):381-389.
18. Starkstein SE, Preziosi TJ, Forrester AW, Robinson RG. Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53(10):869-873.
19. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry. 1992;149(4):443-454.
20. Liu CY, Wang SJ, Fuh JL, Lin CH, Yang YY, Liu HC. The correlation of depression with functional activity in Parkinson's disease. J Neurol. 1997;244(8):493-498.
21. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270(15):1819-1825.
22. Glassman AH, O'Connor CM, Califf RM, et al, for the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709.
23. Leserman J, Jackson ED, Petitto JM. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61(3):397-406.
24. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993;262:1011-1018.
25. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568-2573.
26. Zorilla EP, McKay JR, Luborsky L, Schmidt K. Relation of stressors and depressive symptoms to clinical progression of vital illness. Am J Psychiatry. 1996;153:626-635.
27. Page-Shafer K, Delorenze GN, Satariano W, Winkelstein W Jr. Comorbidity and survival in HIV-infected men in the San Francisco men's health survey. Ann Epidemiol. 1996;6:420-430.
28. Leserman J, Petitto JM, Perkins DO, Folds JD, Golden RN, Evans DL. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. Arch Gen Psychiatry. 1997;54: 279-285.
29. Leserman J, Petitto JM, Gu H. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002;32(6):1059-1073.
30. Williams JB, Rabkin JG, Remien RH, Gorman JM, Ehrhardt AA. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus Infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry. 1991;48(2):124-130.
31. Perry S, Jacobsberg L, Card CA, Ashman T, Frances A, Fishman B. Severity of Psychiatric Symptoms After HIV Testing. Am J Psychiatry. 1993;150(5):775-779.
32. Perkins DO, Stem RA, Golden RN, Murphy C, Naftolowitz D, Evans DL. Mood disorders in HIV infection: Prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry. 1994;151(2):233-236.
33. Lipsitz JD, Williams JB, Rabkin JG, et al. Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry. 1994;151(11):1662-1668.
34. Brown GR, Rundell JR. Prospective study of psychiatric morbidity in HIV-seropositive women without AIDS. Gen Hosp Psychiatry. 1990;12(1):30-35.
35. Goggins K, Engelson ES, Rabkin JG, Kolter D. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med. 1998;60(1):11-16.
36. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial. Am J Psychiatry. 1999;156(1):101-107.
37. Judd FK, Mijch AM, Cockram A. Fluoxetine treatment of depressed patients with HIV infection. Aust N Z J Psychiatry. 1995;29(3):433-436.
38. Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry. 1994;55(3):92-97.
39. Grassi B, Gambini O, Scarone S. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Pharmacopsychiatry. 1995;28(3):93-94.
40. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine. Int J Psychiatry Med. 1995;25(1):53-67.
41. Elliott AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne PP. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 1998;155(3):367-372.
42. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer, diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52(2):89-99.
43. Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry. 1999;60(suppl 40):40-55.
44. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer. 1994;74(9):2570-2578.
45. Carroll BT, Kathol RG, Noyes R Jr, Wald TG, Clamon GH. Screening for depression and anxiety in cancer patients using the hospital anxiety and depression scale. Gen Hosp Psychiatry. 1993;15(2):69-74.
46. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
47. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol. 1998;25(1 Suppl 1):3-8.
48. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-855.
49. Kupfer DJ, Frank JM, Perel CC, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769-773.
50. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kuper DJ, eds. Psychopharmacology: the Fourth Generation of Progress. 4th ed. New York, NY: Raven Press; 1195: 933-944.
51. Golden RN, Heine AD, Ekstrom RD, Bebchuk JM, Leatherman ME, Garbutt JC. A longitudinal study of serotonergic function in depression. Neuropsychopharmacology. 2002;26(5):653-659.
52. Anderson JM, Ware CJ, da Roza Davis JM, Cowen PJ. Decreased 5-HT-mediated prolactin release in major depression. Br J Psychiatry. 1992;160:372-378.
53. Golden RN, Hsiao J, Lane E, et al. Abnormal neuroendocrine responsivity to acute intravenous clomipramine challenge in depressed patients. Psychiatry Res. 1990;31:39-47.
54. Golden RN, Ekstrom D, Brown TB, et al. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry. 1992;149:1168-1175.
55. Golden RN, Ruegg R, Brown T, Haggerty J Jr, Garbutt JC, Pedersen C, Evans DL: Abnormal neuroendocrine responsivity to clomipramine in depression. Psychopharmacol Bull. 1990;26:317-320.
56. Kapitany T, Schindl M, Schindler SD, et al. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res. 1999;88(2):75-88.
57. Sher L, Oquendo MA, Li S, Prolactin response to fenfluramine administration in patients with unipolar and bipolar depression and healthy controls. Psychoneuroendocrinology. 2003;28(4):559-573.
58. Katon W, Robinson P, Von Korff M, et al. A multifacted intervention to improved treatment of depression in primary care. Arch Gen Psychiatry. 1996;53(10):924-932.
59. Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67-74.
60. Katon W, von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30(1): 67-76.
61. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357-366.
62. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56(6):229-237.
63. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1993;13(6 suppl 2):34S-39S.
64. Rothchild AJ. Sexual side effects of antidepressants. J Clin Psychiatry. 2000;61(11):28-35.
65. Baldwin DS, Thomas SC, Brirtwistle J. Effects of antidepressant drugs on sexual function. Int J Psychiatr Clin Pract. 1997;1:47-58.
66. Steffens DC, Krishnan KRK, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-Analysis. Depress Anxiety. 1997;6:10-18.
67. Beasley CM, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuation in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther. 2000;22(11):1319-1330.
68. Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dubé EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry. 2002;63:577-584.
69. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry. 2004;65(2):222-229.
70. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.